MAPT and Alzheimer disease: When considering all neuroinflammatory biomarkers and all recent longitudinal studies, GFAP emerges as the most promising biomarker, effectively tracking reactive astrocytes and enabling the identification of Aβ-positive CU individuals who exhibit early signs of p-tau pathology, with its plasma concentrations being indicative of early-stage dementia and in MCI who progress into AD [175].